Thanks! You've successfully subscribed to the BONEZONE®/OMTEC® Monthly eNewsletter!

Please take a moment to tell us more about yourself and help us keep unwanted emails out of your inbox.

Choose one or more mailing lists:
BONEZONE/OMTEC Monthly eNewsletter
OMTEC Conference Updates
Advertising/Sponsorship Opportunities
Exhibiting Opportunities
* Indicates a required field.

Wright Medical’s AUGMENT Bone Graft Approved by FDA

Wright Medical's BioMimetic subsidiary received FDA approval for its AUGMENT Bone Graft product following delays earlier this year, while a vendor was challenged with an FDA inspection.

Augment is approved for use in ankle and/or hindfoot fusion, and is expected by management to reach $10 million to $12 million in U.S. sales in its first seven to eight months on the market. The company estimates the potential U.S. market at $300 million, assuming use in 100 percent of procedures.

Management also noted Augment’s potential for off-label use in other extremities and orthopaedic procedures, specifically spine and trauma.

Though the product has indicated strong positive clinical evidence from its pivotal trial, analysts say that price ($2,500 to $3,000 per procedure) may affect its ability to pass through increasingly tough hospital value analysis committees. As such, analysts predict that Augment may be limited to higher-risk patients.

Wright’s news came days before U.S. rights to Tornier’s Salto Talaris® and Salto XT™ ankles and the Futura™ silastic toe were picked up by Integra LifeSciences. Regulators requested divestiture of these Tornier products to finalize the company’s merger with Wright. The merger is expected to close in 3Q15.


Security code